Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

ImmunityBio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF MANUFACTURING ENGINEERING PROGRAMS, NK2022 AND NK2023, ESTABLISHING A SAFE, REPRODUCIBLE, AND SCALABLE LEUKAPHERESIS-TO-MANUFACTURING PATHWAY FOR ITS AUTOLOGOUS MEMORY CYTOKINE-ENHANCED NATURAL KILLER (M-CENK) CELL THERAPY PLATFORM. IN ADDITION, A PHASE I PROGRAM (QUILT-3.076; NCT04898543) COMBINING M-CENK WITH ANKTIVA (NOGAPENDEKIN ALFA INBAK.

IMMUNITYBIO ACHIEVES MILESTONE WITH LARGE-SCALE NK CELL PRODUCTION AND CRYOPRESERVATION FROM OVER 60 HEALTHY AND CANCER DONORS

FOLLOWING MULTIPLE MEETINGS WITH THE FDA, IMMUNITYBIO SUBMITTED ADDITIONAL INFORMATION REQUESTED BY THE AGENCY TO SUPPORT ITS SUPPLEMENTAL BLA (SBLA) FOR PAPILLARY DISEASE THE FDA REVIEWED THE ADDITIONAL DATA PROVIDED BY IMMUNITYBIO IN FEBRUARY 2026, AND BASED ON THE AGENCY'S FEEDBACK, THE COMPANY RESUBMITTED THE SBLA THE FDA HAS ACKNOWLEDGED RECEIPT OF THE RESUBMITTED FILING THE SBLA AIMS TO ADDRESS THE UNMET NEED FOR PATIENTS WITH PAPILLARY-ONLY NMIBC, SUPPORTED BY WHAT IS BELIEVED TO BE THE LONGEST DURATION OF FOLLOW-UP AND BLADDER PRESERVATION DATA IN THIS PATIENT POPULATION APPROXIMATELY 60,000 PEOPLE ARE DIAGNOSED WITH NMIBC ANNUALLY IN THE U.S., WITH APPROXIMATELY 70% PRESENTING WITH PAPILLARY (TA) DISEASE1 CULVER CITY, CALIF., MARCH 9, 2026 /PRNEWSWIRE/ -- IMMUNITYBIO (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACKNOWLEDGED RECEIPT OF ITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR ANKTIVA (NOGAPENDEKIN ALFA INBAKICEPT-PMLN) PLUS BACILLUS CALMETTE-GURIN (BCG) IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITHPAPILLARY TUMORS.

IMMUNITYBIO ANNOUNCES RESUBMISSION OF SUPPLEMENTAL BLA TO THE FDA FOR ANKTIVA PLUS BCG IN BCG-UNRESPONSIVE NMIBC WITH PAPILLARY DISEASE FOLLOWING AGENCY REVIEW OF ADDITIONAL DATA

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AT 1:30 P.M. PACIFIC TIME ON TUESDAY, MARCH 3, 2026, TO PROVIDE A BUSINESS UPDATE, INCLUDING PROGRESS ACROSS THE COMPANY'S CLINICAL TRIAL PIPELINE, AND TO REVIEW FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025. CONFERENCE CALL DETAILS THE CONFERENCE CALL WILL BEGIN AT 1:30 P.M. PACIFIC TIME (4:30 P.M. EASTERN TIME) ON TUESDAY, MARCH 3, 2026. INTERESTED PARTIES.

IMMUNITYBIO TO PROVIDE A BUSINESS UPDATE AND REVIEW FINANCIAL RESULTS FOR FY 2025 ON TUESDAY, MARCH 3, 2026

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED COMPLETION OF ENROLLMENT IN ITS PHASE 2 CLINICAL TRIAL EVALUATING ANKTIVA (NOGAPENDEKIN ALFA INBAKICEPT-PMLN) PLUS BACILLUS CALMETTE-GURIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH BCG-NAVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN SITU (CIS), WITH OR WITHOUT PAPILLARY TUMORS. THE QUILT 2.005 TRIAL (NCT02138734), WHICH COMPLETED ENROLLMENT AHEAD OF SCHEDULE,.

IMMUNITYBIO COMPLETES ENROLLMENT IN PIVOTAL RANDOMIZED TRIAL EVALUATING ANKTIVA PLUS BCG VERSUS BCG ALONE IN BCG-NAVE NON-MUSCLE INVASIVE BLADDER CANCER CARCINOMA IN SITU

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING NEXT-GENERATION IMMUNOTHERAPIES, TODAY ANNOUNCED THAT ITS FOUNDER, EXECUTIVE CHAIRMAN, AND GLOBAL CHIEF SCIENTIFIC AND MEDICAL OFFICER, DR. PATRICK SOON-SHIONG, WILL PARTICIPATE AS A FEATURED SPEAKER AT "CANCER 2035: A ROADMAP FOR THE FUTURE," A LANDMARK SUMMIT CO-HOSTED BY THE MILKEN INSTITUTE AND THE RICHARD NIXON FOUNDATION IN WASHINGTON, D.C. ON FEBRUARY 2324, 2026. T.

IMMUNITYBIO FOUNDER DR. PATRICK SOON-SHIONG TO SPEAK AT MILKEN INSTITUTE AND RICHARD NIXON FOUNDATION "CANCER 2035: A ROADMAP FOR THE FUTURE" SUMMIT

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED FULL-YEAR 2025 FINANCIAL AND OPERATIONAL HIGHLIGHTS, INCLUDING APPROXIMATELY $113 MILLION IN NET PRODUCT REVENUE FOR ANKTIVA, REPRESENTING AN APPROXIMATELY 700% INCREASE YEAR-OVER-YEAR. THE COMPANY ALSO REPORTED A 750% INCREASE IN UNIT SALES VOLUME AND A 20% QUARTER-OVER-QUARTER INCREASE IN NET PRODUCT REVENUE, DEMONSTRATING SUSTAINED COMMERCIAL MOMENTUM. IN PARALLEL.

IMMUNITYBIO REPORTS 700% YEAR-OVER-YEAR REVENUE GROWTH, EXPANDED ANKTIVA APPROVALS IN LUNG CANCER AND GLOBAL COMMERCIAL PARTNERSHIPS IN 33 COUNTRIES WITH LABEL EXPANSION PLANS GLOBALLY

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED A PARTNERSHIP WITH BIOPHARMA AND CIGALAH, TWO OF THE LARGEST AND MOST RESPECTED HEALTHCARE COMMERCIAL AND DISTRIBUTION COMPANIES IN THE MIDDLE EAST, TO LAUNCH ANKTIVA (NOGAPENDEKIN ALFA INBAKICEPT) IN SAUDI ARABIA AND, OVER TIME, ACROSS THE BROADER MENA REGION. UNDER THE AGREEMENT, BIOPHARMA AND CIGALAH HEALTHCARE WILL SUPPORT THE COMMERCIALIZATION AND DISTRIBUTION.

IMMUNITYBIO PARTNERS WITH BIOPHARMA AND CIGALAH HEALTHCARE TO LAUNCH ANKTIVA IN SAUDI ARABIA FOR BLADDER AND LUNG CANCER PATIENTS

NEW YORK, FEB. 19, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF IMMUNITYBIO, INC. ("IMMUNITYBIO" OR THE "COMPANY") (NASDAQ: IBRX).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF IMMUNITYBIO, INC. - IBRX

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED A PARTNERSHIP WITH ACCORD HEALTHCARE TO PROVIDE ACCESS TO ANKTIVA (NOGAPENDEKIN ALFA INBAKICEPT) IN COMBINATION WITH BACILLUS CALMETTE-GURIN (BCG) FOR ELIGIBLE PATIENTS IN THE EUROPEAN UNION WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER CARCINOMA IN SITU (NMIBC CIS), WITH OR WITHOUT PAPILLARY DISEASE. IMMUNITYBIO ALSO ANNOUNCED THE ESTABLISHMENT OF AN IR.

IMMUNITYBIO EXPANDS ACCESS TO ANKTIVA IN EU WITH NEW DISTRIBUTION PARTNERSHIP AND OPENS IRISH SUBSIDIARY TO SUPPORT EUROPEAN LAUNCH

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION HAS GRANTED CONDITIONAL MARKETING AUTHORIZATION FOR ANKTIVA (NOGAPENDEKIN ALFA INBAKICEPT) IN COMBINATION WITH BACILLUS CALMETTE-GURIN (BCG) FOR THE TREATMENT OF ADULT PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN SITU (CIS), WITH OR WITHOUT PAPILLARY TUMORS. ANKTIVA IN COMBINATION WITH BCG IS THE FIRS.

IMMUNITYBIO RECEIVES AUTHORIZATION FROM THE EUROPEAN COMMISSION FOR ANKTIVA WITH BCG FOR NON-MUSCLE INVASIVE BLADDER CANCER CARCINOMA IN SITU, EXPANDING GLOBAL ACCESS TO 33 COUNTRIES

NEW YORK, FEB. 17, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF IMMUNITYBIO, INC. (IMMUNITYBIO OR THE COMPANY) (NASDAQ: IBRX).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORSOFIMMUNITYBIO, INC. - IBRX

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NYSE: IBRX), A COMMERCIAL STAGE IMMUNOTHERAPY COMPANY DEVELOPING NEXT GENERATION THERAPIES THAT DRIVE IMMUNOLOGICAL MEMORY AND RESTORE IMMUNE COMPETENCE, TODAY ANNOUNCED THAT THE COMPANY HELD PRODUCTIVE REGULATORY DISCUSSIONS WITH THE SAUDI FOOD AND DRUG AUTHORITY (SFDA) IN RIYADH, CONVENED UNDER THE SAUDI-USA BIOTECH ALLIANCE HOSTED BY THE MINISTRY OF INVESTMENT OF SAUDI ARABIA (MISA). THE ENGAGEMENT ADVANCED TWO REGULATORY PRIORITIES: (.

IMMUNITYBIO REPORTS PRODUCTIVE REGULATORY ENGAGEMENT WITH SAUDI FOOD AND DRUG AUTHORITY AT USA-SAUDI BIOTECH ALLIANCE MEETING HOSTED BY THE MINISTRY OF INVESTMENT OF SAUDI ARABIA

NEW YORK, FEB. 12, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF IMMUNITYBIO, INC. ("IMMUNITYBIO" OR THE "COMPANY") (NASDAQ: IBRX).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THE LAUNCH OF RESQ215B, A PHASE 2 CLINICAL STUDY EVALUATING A NOVEL CHEMOTHERAPY-FREE AND LYMPHODEPLETION-FREE COMBINATION IMMUNOTHERAPY IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA (INHL), INCLUDING WALDENSTRM'S MACROGLOBULINEMIA. THE OUTPATIENT STUDY EVALUATES IMMUNITYBIO'S NOVEL, OFF-THE-SHELF CD19-TARGETED HIGH-AFFINITY NATURAL KILLER (NK) CELL THERAPY.

IMMUNITYBIO LAUNCHES PHASE 2 CHEMOTHERAPY-FREE CAR-NK CELL THERAPY TRIAL WITH ANKTIVA (RESQ215B) IN INDOLENT LYMPHOMAS

NEW YORK, JAN. 29, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF IMMUNITYBIO, INC. ("IMMUNITYBIO" OR THE "COMPANY") (NASDAQ: IBRX). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK, JAN. 27, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF IMMUNITYBIO, INC. (IMMUNITYBIO OR THE COMPANY) (NASDAQ: IBRX).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY DEVELOPING CYTOKINE AND CELLULAR IMMUNOTHERAPIES DESIGNED TO RESTORE IMMUNE COMPETENCE, TODAY ANNOUNCED UPDATED PHASE 2 CLINICAL RESULTS FROM QUILT 3.078 (NCT06061809), EVALUATING A CHEMOTHERAPY-FREE COMBINATION IMMUNOTHERAPY REGIMEN IN PATIENTS WITH SECOND-LINE RECURRENT OR PROGRESSIVE GLIOBLASTOMA (GBM), AS WELL AS PATIENTS TREATED UNDER SINGLE-PATIENT INDS (SPINDS) ACROSS FIRST- T.

IMMUNITYBIO REPORTS MEDIAN OVERALL SURVIVAL NOT YET REACHED AND LYMPHOPENIA REVERSED IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING ANKTIVA PLUS CAR-NK, CHEMO-FREE THERAPY

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A CLINICAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT IT RECENTLY HELD A TYPE B END-OF-PHASE MEETING WITH THE U.S. FDA REGARDING THE COMPANY'S SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR ANKTIVA (NOGAPENDEKIN ALFA INBAKICEPT) PLUS BACILLUS CALMETTE-GURIN (BCG) IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH PAPILLARY TUMORS. THE COMPANY PRESENTED AN OVERVIEW OF THE CLINICAL STATUS OF I.

IMMUNITYBIO ADVANCES REGULATORY DISCUSSIONS WITH FDA ON POTENTIAL RESUBMISSION PATH FOR ANKTIVA IN BCG-UNRESPONSIVE PAPILLARY BLADDER CANCER

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX) TODAY ANNOUNCED AN UPDATE ON THE STATUS OF ENROLLMENT IN ITS RANDOMIZED REGISTRATIONAL TRIAL IN BCG-NAVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC), QUILT-2.005. ENROLLMENT HAS EXCEEDED INTERNAL EXPECTATIONS AND IS NOW OVER 85% COMPLETE, WITH FULL ENROLLMENT OF THE PLANNED STUDY POPULATION ANTICIPATED BY Q2 2026. BASED ON THE CURRENT ENROLLMENT TRAJECTORY, IMMUNITYBIO ANTICIPATES SUBMITTING A BIOLOGICS LICENSE APPLICATION (.

IMMUNITYBIO ADVANCES FIRST-LINE BCG NAIVE NMIBC PROGRAM WITH ENROLLMENT EXCEEDING EXPECTATIONS AND POSITIVE INTERIM ANALYSIS FOR ANKTIVA PLUS BCG

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED UPDATED EFFICACY AND SAFETY RESULTS FROM THE ONGOING QUILT-106 CLINICAL STUDY (NCT06334991) EVALUATING AN OFF-THE-SHELF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELL THERAPY (CAR-NK). THIS CD19 T-HANK (CAR-NK) IS A TARGETED HIGH-AFFINITY NATURAL KILLER (NK) CELL THERAPY ENGINEERED TO EXPRESS A CD19-SPECIFC CHIMERIC ANTIGEN RECEPTOR (CAR) USED IN COMBI.

IMMUNITYBIO ANNOUNCES DURABLE COMPLETE RESPONSE OF 15 MONTHS WITH A CHEMOTHERAPY-FREE CD19 CAR-NK CELL THERAPY IN WALDENSTROM LYMPHOMA

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A VERTICALLY-INTEGRATED COMMERCIAL STAGE BIOTECHNOLOGY COMPANY, ANNOUNCED TODAY PRELIMINARY SELECT OPERATIONAL RESULTS FOR THE FISCAL QUARTER AND FULL YEAR ENDING DECEMBER 31, 2025. IMMUNITYBIO REPORTED PRELIMINARY NET PRODUCT REVENUE OF APPROXIMATELY $38.3 MILLION DURING THE THREE-MONTH PERIOD ENDING DECEMBER 31, 2025, WHICH REPRESENTED AN INCREASE OF 20% OVER THE $31.8 MILLION OF NET PRODUCT REVENUE EARNED DURING THE THIR.

IMMUNITYBIO REPORTS CONTINUED EXECUTION AND SALES MOMENTUM WITH $113 MILLION OF PRELIMINARY NET PRODUCT REVENUEA 700% INCREASE YEAR-OVER-YEAR

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT THE SAUDI FOOD AND DRUG AUTHORITY (SFDA) HAS GRANTED ACCELERATED APPROVAL OF ANKTIVA (NOGAPENDEKIN ALFA INBAKICEPT) FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED FOLLOWING STANDARD-OF-CARE THERAPY. THIS MARKS THE FIRST APPROVAL OF THE C.

SAUDI FDA GRANTS ACCELERATED APPROVAL TO IMMUNITYBIO'S ANKTIVA IN COMBINATION WITH CHECKPOINT INHIBITORS FOR METASTATIC NON-SMALL CELL LUNG CANCER

CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT THE SAUDI FOOD AND DRUG AUTHORITY (SFDA) HAS GRANTED APPROVAL OF ANKTIVA (NOGAPENDEKIN ALFA INBAKICEPT) PLUS BACILLUS CALMETTE-GURIN (BCG) FOR THE TREATMENT OF ADULT PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER CARCINOMA IN SITU, WITH OR WITHOUT PAPILLARY DISEASE. THIS REGULATORY ACTION BY THE SFDA ADDS TO THE EXISTING APPROVALS IN THE UNI.

ImmunityBio, Inc.

IBRX

Price

Financial Reports

No items found.

Press Releases

ImmunityBio, Inc.

IBRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IBRX